It hasn’t been few weeks for COVID-19 vaccines. Over the previous few weeks, a quantity of international locations have drastically restricted the use of the AstraZeneca vaccine due to blood clot fears in youthful folks. Now, the USA Meals and Drug Administration (FDA) has introduced it’s recommending all states pause the administration of the Johnson & Johnson vaccine attributable to blood clotting points as effectively.
— U.S. FDA (@US_FDA) April 13, 2021
The FDA says that as of April 12, over 6.8 million doses of the Johnson & Johnson vaccine have been administered within the U.S. with six reported instances of “a uncommon and extreme kind of blood clot” in individuals who acquired the vaccine. The FDA says the Facilities for Illness Management and Prevention (CDC) will convene a gathering of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to assessment the reported instances and decide how vital they’re. Till then, the FDA is recommending states pause the Johnson & Johnson rollout.
“That is necessary to make sure that the well being care supplier neighborhood is conscious of the potential for these antagonistic occasions and might plan as a result of distinctive remedy required with this sort of blood clot,” the company says.